Search Clinical Trials
Sponsor Condition of Interest |
---|
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2...
Jonsson Comprehensive Cancer Center
Early-stage Breast Cancer
Hormone Receptor Positive Breast Carcinoma
Invasive Breast Cancer
Stage II Breast Cancer
Stage IIA Breast Cancer
This phase II trial investigates how well trastuzumab deruxtecan works alone or in
combination with anastrozole in treating patients with HER2 low, hormone receptor
positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called
trastuzumab, linked to a chemotherapy drug called deruxtecan.... expand
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole. Type: Interventional Start Date: Oct 2020 |
Bladder Fiducial Markers and Multiparametric-MRI (mp-MRI) to Optimize Bladder Chemo-radiotherapy
Cedars-Sinai Medical Center
Bladder Cancer
Urinary Bladder Neoplasm
Urologic Neoplasms
Neoplasms
Urinary Bladder Diseases
The purpose of this study is to examine the usefulness of implanting small 24-K gold
fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify
the original tumor location at the time of radiation treatment. Other goals of the study
include assessing whether a new MRI... expand
The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI imaging technology can help with detection of bladder cancer earlier and more accurately when evidence of bladder cancer is not visible by scope. Type: Interventional Start Date: Jul 2020 |
MitraClip REPAIR MR Study
Abbott Medical Devices
Mitral Valve Regurgitation
The objective of this randomized controlled trial (RCT) is to compare the clinical
outcome of MitraClip™ device versus surgical repair in patients with severe primary MR
who are at moderate surgical risk and whose mitral valve has been determined to be
suitable for correction by MV repair surgery... expand
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team. Type: Interventional Start Date: Jul 2020 |
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and...
National Cancer Institute (NCI)
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
This phase III trial studies if selumetinib works just as well as the standard treatment
with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma
(LGG), and to see if selumetinib is better than CV in improving vision in subjects with
LGG of the optic pathway (vision nerves).... expand
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine. Type: Interventional Start Date: Jan 2020 |
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Daiichi Sankyo Co., Ltd.
Hormone Receptor Positive Breast Cancer
Triple Negative Breast Cancer
Non-small Cell Lung Cancer
This study is one single group of participants with non-small cell lung cancer (NSCLC)
who have not been cured by other treatments. It is the first time the drug has been used
in humans. There will be two parts and a sub-study.
The primary purpose of the parts are:
- Dose Escalation: To investigate... expand
This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: - Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a - Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are located in both the United States and Japan. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: - they withdraw - their disease gets worse - they experience unacceptable side effects. The primary purpose of the sub-study is to compare the effectiveness of steroid versus non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants receiving DS-1062a. The sub-study is a randomized study that will include approximately 76 participants enrolling into the Dose Expansion part. Type: Interventional Start Date: Jan 2018 |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Histiocytic Sarcoma
Juvenile Xanthogranuloma
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well
treatment that is directed by genetic testing works in pediatric patients with solid
tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at
least one line of standard systemic therapy... expand
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. Type: Interventional Start Date: Jul 2017 |
Ziftomenib Maintenance Post Allo-HCT
Massachusetts General Hospital
Acute Myeloid Leukemia
Acute Myeloid Leukemia in Remission
NPM1 Mutation
KMT2A Rearrangement
The purpose of this study is to test the safety, effects, and recommended dose of an
investigational drug, ziftomenib, in addition to the standard treatment on blood cancer
with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn
more about ziftomenib, which targets... expand
The purpose of this study is to test the safety, effects, and recommended dose of an investigational drug, ziftomenib, in addition to the standard treatment on blood cancer with Allogeneic Hematopoietic Cell Transplantation (allo-HCT). This study plans to learn more about ziftomenib, which targets and inhibits negative interactions within cancer cells related to AML, when given after allo-HCT, to determine if it improves outcomes following allo-HCT. The name of the study drug involved in this study is: • Ziftomenib Type: Interventional Start Date: Jun 2024 |
Epilepsy Learning Healthcare System (ELHS)
Epilepsy Foundation of America
Epilepsy
Seizure Disorder
Neurologic Disorder
Rare Diseases
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network
to improve outcomes for people with epilepsy. The ELHS is designed as a model of
value-based chronic care for epilepsy as envisioned by the National Academies of Medicine
Committee in their landmark reports "The... expand
The Epilepsy Learning Health System (ELHS) is a quality improvement and research network to improve outcomes for people with epilepsy. The ELHS is designed as a model of value-based chronic care for epilepsy as envisioned by the National Academies of Medicine Committee in their landmark reports "The Learning Health System" and "Epilepsy Across the Spectrum: Promoting Health and Understanding". The ELHS network is a collaboration among clinicians, patients and researchers that promotes the use of data for multiple purposes including one-on-one clinical care, population management, quality improvement and research. The ELHS Registry includes data on children and adults with epilepsy collected during the process of standard epilepsy care. These data are used to create population health reports and to track changes in outcomes over time. ELHS teams use quality improvement methods, such as Plan-Do-Study-Act (PDSA) cycles, to continuously learn how to improve care. Type: Observational [Patient Registry] Start Date: Mar 2019 |
Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With...
Sol-Gel Technologies, Ltd.
Gorlin Syndrome
The aim of this clinical study is to find out how well Patidegib Gel 2% works in
preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin
syndrome, and how safe Patidegib Gel 2% is to use.
Participants will apply either Patidegib Gel 2% or a Vehicle Gel (with no active... expand
The aim of this clinical study is to find out how well Patidegib Gel 2% works in preventing new basal cell carcinomas (BCCs) developing on the face of adults with Gorlin syndrome, and how safe Patidegib Gel 2% is to use. Participants will apply either Patidegib Gel 2% or a Vehicle Gel (with no active drug substance) to their face twice a day for a year (12 months). The number of new BCCs on the face will be compared between participants who used Patidegib Gel 2% or Vehicle Gel after 12 months. Type: Interventional Start Date: Mar 2024 |
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Washington University School of Medicine
Surgery-Complications
Anesthesia Complication
Anesthesia Awareness
Anesthesia
Surgery
The investigators will conduct a 12,500-patient randomized multi-center trial to
determine (i) which general anesthesia technique yields superior patient recovery
experiences in any of three surgical categories ((a) major inpatient surgery, (b) minor
inpatient surgery, (c) outpatient surgery) and... expand
The investigators will conduct a 12,500-patient randomized multi-center trial to determine (i) which general anesthesia technique yields superior patient recovery experiences in any of three surgical categories ((a) major inpatient surgery, (b) minor inpatient surgery, (c) outpatient surgery) and (ii) whether TIVA confers no more than a small (0.2 %) increased risk of intraoperative awareness than INVA in patients undergoing both outpatient and inpatient surgeries Type: Interventional Start Date: Sep 2023 |
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
HistoSonics, Inc.
Renal Cancer
Tumor, Solid
Kidney Cancer
Tumor
Tumor, Benign
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics
Edison System for the destruction of kidney tissue by treating primary solid renal
tumors. expand
The purpose of this trial is to evaluate the effectiveness and safety of the HistoSonics Edison System for the destruction of kidney tissue by treating primary solid renal tumors. Type: Interventional Start Date: Jan 2024 |
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
Cook MyoSite
Fecal Incontinence
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x
10^6 cells) compared to a placebo in the reduction of fecal incontinence episode
frequency in adult female participants with chronic fecal incontinence and a history of
obstetric anal sphincter injury. Half of... expand
This study evaluates the efficacy and safety of a single injection of iltamiocel (300 x 10^6 cells) compared to a placebo in the reduction of fecal incontinence episode frequency in adult female participants with chronic fecal incontinence and a history of obstetric anal sphincter injury. Half of the participants will receive iltamiocel (injections with cells) and the other half will receive placebo. Type: Interventional Start Date: Mar 2024 |
Intermuscular Coherence as a Biomarker for ALS
University of Chicago
Amyotrophic Lateral Sclerosis
The specific aims of this study are to:
1. Determine if a painless and quick measurement of muscle activity using surface
electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of
intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji... expand
The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria), can differentiate ALS from mimic diseases more accurately and earlier than currently possible. 2. Characterize IMC-βγ in neurotypical subjects by age, sex, race, and ethnicity. 3. Follow a cohort of ALS patients longitudinally to determine if IMC-βγ changes with ALS disease progression and whether such changes correlate with functional and clinical scores, or survival. Type: Observational Start Date: Mar 2021 |
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Neovasc Inc.
Refractory Angina
To demonstrate the safety and effectiveness of the Reducer system for treatment of
patients with refractory angina pectoris treated with maximally tolerated
guideline-directed medical therapy who demonstrate objective evidence of reversible
myocardial ischemia in the distribution of the left coronary... expand
To demonstrate the safety and effectiveness of the Reducer system for treatment of patients with refractory angina pectoris treated with maximally tolerated guideline-directed medical therapy who demonstrate objective evidence of reversible myocardial ischemia in the distribution of the left coronary artery and who are deemed unsuitable for revascularization. A non-randomized single-arm will further assess the safety and effectiveness of the Neovasc Reducer System in selected subjects with reversible myocardial ischemia in the distribution of the right coronary artery and who are deemed unsuitable for revascularization, subjects with reversible myocardial ischemia without documented obstructive coronary disease and subjects who cannot complete an exercise tolerance test due to an above-the-ankle amputation. Type: Interventional Start Date: Jan 2022 |
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
Massachusetts General Hospital
Unresectable Hepatocellular Carcinoma
This research study is evaluating the safety and tolerability of the drugs atezolizumab
and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable
hepatocellular carcinoma.
This study involves the following interventions:
- Atezolizumab
- Bevacizumab... expand
This research study is evaluating the safety and tolerability of the drugs atezolizumab and bevacizumab with stereotactic body radiation therapy (SBRT) for treating unresectable hepatocellular carcinoma. This study involves the following interventions: - Atezolizumab - Bevacizumab - Stereotactic body radiation therapy (SBRT) Type: Interventional Start Date: Aug 2022 |
Cannabidiol for Reduction of Brain Neuroinflammation
Massachusetts General Hospital
Back Pain
Depressive Symptoms
This study will investigate whether cannabidiol (CBD), the primary centrally and
peripherally active non-intoxicating compound in the cannabis plant, exerts
anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or
without mild-to-moderate depression. expand
This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression. Type: Interventional Start Date: Jan 2022 |
The ENCIRCLE Trial
Edwards Lifesciences
Mitral Regurgitation
Mitral Valve Insufficiency
This study will establish the safety and effectiveness of the SAPIEN M3 System in
subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially
available surgical or transcatheter treatment options are deemed unsuitable.
Following completion of enrollment, subjects will... expand
This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available surgical or transcatheter treatment options are deemed unsuitable. Following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial. Type: Interventional Start Date: Nov 2020 |
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Icahn School of Medicine at Mount Sinai
Atrial Fibrillation
Stroke
Bleeding
The primary objective of this study is to evaluate the effectiveness (prevention of
thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC)
to background antiplatelet therapy in patients who develop new-onset post-operative
atrial fibrillation (POAF) after isolated... expand
The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying POAF event, who decline randomization, will be offered the option of enrollment in a parallel registry that captures their baseline risk profile and their treatment strategy in terms of anticoagulants or antiplatelets received. These patients will also be asked to fill out a brief decliner survey. Type: Interventional Start Date: Dec 2019 |
Developing Fast Pediatric Imaging
Boston Children's Hospital
Pediatric Low-grade Gliomas
This research study is evaluating the investigational software for magnetic resonance
imaging (MRI) systems and techniques to process magnetic resonance (MR) images expand
This research study is evaluating the investigational software for magnetic resonance imaging (MRI) systems and techniques to process magnetic resonance (MR) images Type: Interventional Start Date: Apr 2019 |
Skilled Nursing Facility Care at Home
Brigham and Women's Hospital
Skilled Nursing Facility
Rehabilitation
We will perform a parallel-group multicenter patient-level randomized controlled
evaluation of skilled nursing facility care at home. Patients typically referred to a
skilled nursing facility following hospitalization will be eligible for enrollment.
Instead of admission to a skilled nursing facility,... expand
We will perform a parallel-group multicenter patient-level randomized controlled evaluation of skilled nursing facility care at home. Patients typically referred to a skilled nursing facility following hospitalization will be eligible for enrollment. Instead of admission to a skilled nursing facility, participants will receive care from a technology-enabled team in their own homes or will be allocated to receive care in a traditional skilled nursing facility setting. Type: Interventional Start Date: Jun 2024 |
A Study of EDG-7500 in Adults with Hypertrophic Cardiomyopathy (CIRRUS-HCM)
Edgewise Therapeutics, Inc.
Hypertrophic Cardiomyopathy
This study is being conducted in order to understand the safety and effects of different
doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy
and as multiple doses in adults with obstructive or nonobstructive hypertrophic
cardiomyopathy. expand
This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy and as multiple doses in adults with obstructive or nonobstructive hypertrophic cardiomyopathy. Type: Interventional Start Date: Apr 2024 |
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
MGH Institute of Health Professions
Copd
COPD Exacerbation
COPD Bronchitis
Emphysema or COPD
Chronic Lung Disease
The goal of this pilot clinical trial is to compare telehealth and onsite supervised
maintenance exercise program for adults with Chronic Lung Disease.
The specific aims of the study are:
- To compare 8-week supervised maintenance program delivered onsite and via tele-rehab
with no maintenance... expand
The goal of this pilot clinical trial is to compare telehealth and onsite supervised maintenance exercise program for adults with Chronic Lung Disease. The specific aims of the study are: - To compare 8-week supervised maintenance program delivered onsite and via tele-rehab with no maintenance for patients with Chronic Lung Disease following discharge from traditional exercise or physical therapy or onsite outpatient rehabilitation programs on clinical outcomes (dyspnea, exercise capacity, physical function, physical activity, and quality of life) at 8 weeks and 4-months post-intervention. - To compare the differences in dyspnea, exercise capacity, physical function, physical activity, and quality of life between an 8-week maintenance program delivered onsite and via tele-rehab at 8-weeks and 4-months post-intervention in patients with Chronic Lung Disease following discharge from traditional onsite outpatient rehabilitation. Participants in both intervention groups (onsite and tele-rehab) will undergo a baseline onsite assessment followed by an 8-week supervised exercise intervention either onsite or in a telehealth setting. Control group will receive biweekly check in calls, but no active intervention. Type: Interventional Start Date: Sep 2023 |
Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy
Massachusetts General Hospital
Myotonic Dystrophy Type 1
Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness,
diminished working memory, impaired visuospatial skills, and deficits in problem-solving
skills.
Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the
brain.
Changes in the... expand
Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in brain activity and function. The purpose of this research is to learn about myotonic dystrophy by examining cerebrospinal fluid and brain activity in participants. The tests will be low risk and are well tolerated. The information that we gather from this study may help us evaluate, prevent, diagnose, treat, and improve our understanding of myotonic dystrophy. Funding Source- FDA OOPD Type: Observational Start Date: Aug 2022 |
Building Resiliency Among Caregivers of Curvivors and Metavivors
Massachusetts General Hospital
Stress
Cancer Diagnosis
Distress, Emotional
The main purpose of this research study is to assess the feasibility and participants'
satisfaction of the Stress Management and Resiliency - Relaxation Response Resiliency
Program (SMART-3RP) and compare this treatment with SMART-3RP versus referral to a
group-based, online support group to see which... expand
The main purpose of this research study is to assess the feasibility and participants' satisfaction of the Stress Management and Resiliency - Relaxation Response Resiliency Program (SMART-3RP) and compare this treatment with SMART-3RP versus referral to a group-based, online support group to see which is better for improving resilience and decreasing distress of participants with cancer and their caregivers. The name of the study intervention involved in this study is: Smart-3RP (virtual, mind-body group treatment program). Type: Interventional Start Date: Jun 2023 |
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation...
Oryzon Genomics S.A.
Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory
Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+).
During the trial, iadademstat will be given in combination with gilteritinib, a drug that
is already approved to treat patients... expand
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML. Type: Interventional Start Date: Nov 2022 |
- Previous
- Next